PBI 4050

BI-4050 is an orally active lead drug candidate with excellent safety and efficacy profiles confirmed in several in vivo experiments targeting fibrosis indications being pursued for PBI-4050 include Idiopathic Pulmonary Fibrosis (IPF), Alström syndrome, Chronic Kidney Diseases (CKD)/Diabetic Kidney Diseases(DKD), Metabolic Syndrome and much more...